Correlation Between Unicycive Therapeutics and Dermata Therapeutics

Can any of the company-specific risk be diversified away by investing in both Unicycive Therapeutics and Dermata Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Unicycive Therapeutics and Dermata Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Unicycive Therapeutics and Dermata Therapeutics Warrant, you can compare the effects of market volatilities on Unicycive Therapeutics and Dermata Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Unicycive Therapeutics with a short position of Dermata Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Unicycive Therapeutics and Dermata Therapeutics.

Diversification Opportunities for Unicycive Therapeutics and Dermata Therapeutics

-0.28

Correlation Coefficient

Unicycive Therapeutics  Dermata Therapeutics

Very good diversification

The 3 months correlation between Unicycive and Dermata is -0.28. Overlapping area represents the amount of risk that can be diversified away by holding Unicycive Therapeutics and Dermata Therapeutics Warrant in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Dermata Therapeutics and Unicycive Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Unicycive Therapeutics are associated (or correlated) with Dermata Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Dermata Therapeutics has no effect on the direction of Unicycive Therapeutics i.e., Unicycive Therapeutics and Dermata Therapeutics go up and down completely randomly.

Pair Corralation between Unicycive Therapeutics and Dermata Therapeutics

Given the investment horizon of 90 days Unicycive Therapeutics is expected to generate 138.71 times less return on investment than Dermata Therapeutics. But when comparing it to its historical volatility, Unicycive Therapeutics is 29.11 times less risky than Dermata Therapeutics. It trades about 0.04 of its potential returns per unit of risk. Dermata Therapeutics Warrant is currently generating about 0.2 of returns per unit of risk over similar time horizon. If you would invest  1.21  in Dermata Therapeutics Warrant on September 4, 2024 and sell it today you would lose (0.33) from holding Dermata Therapeutics Warrant or give up 27.27% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	48.99%
Values	Daily Returns

Unicycive Therapeutics  vs.  Dermata Therapeutics Warrant

Unicycive Therapeutics

Risk-Adjusted Performance

19 of 100

Solid

Compared to the overall equity markets, risk-adjusted returns on investments in Unicycive Therapeutics are ranked lower than 19 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak fundamental indicators, Unicycive Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Dermata Therapeutics

Risk-Adjusted Performance

0 of 100

Solid

Over the last 90 days Dermata Therapeutics Warrant has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly conflicting basic indicators, Dermata Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Unicycive Therapeutics and Dermata Therapeutics

The main advantage of trading using opposite Unicycive Therapeutics and Dermata Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Unicycive Therapeutics position performs unexpectedly, Dermata Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Dermata Therapeutics will offset losses from the drop in Dermata Therapeutics' long position.

The idea behind Unicycive Therapeutics and Dermata Therapeutics Warrant pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.